Lantheus buys Life Molecular Imaging for $350M, targeting Alzheimer's diagnostics boost.
Lantheus Holdings acquired Life Molecular Imaging Ltd for $350 million, with potential for an additional $400 million in future payments. This deal enhances Lantheus' capabilities in Alzheimer's disease diagnostics, particularly with Neuraceq, a PET imaging agent for detecting beta-amyloid plaques. The acquisition aims to boost Lantheus' EPS within a year and strengthen its radiopharmaceutical portfolio and R&D.
2 months ago
10 Articles